Pubblicazioni

Autori:

Merz, Valeria; Mangiameli, Domenico; Zecchetto, Camilla; Quinzii, Alberto; Pietrobono, Silvia; Messina, Carlo; Casalino, Simona; Gaule, Marina; Pesoni, Camilla; Vitale, Pasquale; Trentin, Chiara; Frisinghelli, Michela; Caffo, Orazio; Melisi, Davide

Titolo:

Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer

Anno:

2022

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

FRONTIERS IN SURGERY

ISSN Rivista:

2296-875X

N° Volume:

9

Intervallo pagine:

866173-866185

Parole chiave:

microbiota; molecular profiling; neoadjuvant therapy; predictive factors; preoperative treatment; resectable pancreatic cancer; target therapy; tumor microenvironment

Breve descrizione dei contenuti:

The mainstay treatment for patients with immediate resectable pancreatic cancer remains upfront surgery, which represents the only potentially curative strategy. Nevertheless, the majority of patients surgically resected for pancreatic cancer experiences disease relapse, even when a combination adjuvant therapy is offered. Therefore, aiming at improving disease free survival and overall survival of these patients, there is an increasing interest in evaluating the activity and efficacy of neoadjuvant and perioperative treatments. In this view, it is of utmost importance to find biomarkers able to select patients who may benefit from a preoperative therapy rather than upfront surgical resection. Defined genomic alterations and a dynamic inflammatory microenvironment are the major culprits for disease recurrence and resistance to chemotherapeutic treatments in pancreatic cancer patients. Signal transduction pathways or tumor immune microenvironment could predict early recurrence and response to chemotherapy. In the last decade, distinct molecular subtypes of pancreatic cancer have been described, laying the bases to a tailored therapeutic approach, started firstly in the treatment of advanced disease. Patients with homologous repair deficiency, in particular with mutant germline BRCA genes, represent the first subgroup demonstrating to benefit from specific therapies. A fraction of patients with pancreatic cancer could take advantage of genome sequencing with the aim of identifying possible targetable mutations. These genomic driven strategies could be even more relevant in a potentially curative setting. In this review, we outline putative predictive markers that could help in the next future in tailoring the best therapeutic strategy for pancreatic cancer patients with a potentially curable disease.

Id prodotto:

132335

Handle IRIS:

11562/1087018

ultima modifica:

28 marzo 2023

Citazione bibliografica:

Merz, Valeria; Mangiameli, Domenico; Zecchetto, Camilla; Quinzii, Alberto; Pietrobono, Silvia; Messina, Carlo; Casalino, Simona; Gaule, Marina; Pesoni, Camilla; Vitale, Pasquale; Trentin, Chiara; Frisinghelli, Michela; Caffo, Orazio; Melisi, Davide, Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer «FRONTIERS IN SURGERY» , vol. 9 , 2022 , pp. 866173-866185

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo